Cardiovascular disturbances and atherosclerosis risk Гасtore in systemic lupus erythematosus
https://doi.org/10.14412/1995-4484-2004-795
Abstract
Objective. To assess frequency and significance of atherosclerosis and connected with it cardiovascular disturbances (CVD) risk factors in pts wilh systemic lupus erythematosus (SLE). Material and methods. 99 pts (mean age 35,9± 10,8 years, mean disease duration 106± 115,5 months) were examined. Classical risk factors were analyzed. Coronary complications risk was assessed with "Scheme of individual total (general) coronary heart disease (CHD) clinical signs risk determination”. Duplex scanning of common carotid arteries was performed. C-reactive protein (CRP) was evaluated by high-sensitivity immune-enzyme assay with Bender MedSystems commercial kits. Results. 92% of SLE pts had at least one classical atherosclerosis risk factor, most often - dislipidemia (DLP) or hypertension (HT). Subclinical atherosclerosis signs characterized by increase of intima-media complex thickness and DLP were more frequent in pts with HT than without HT (p=0,00l and p=0,008 respectively. Total CHD clinical signs risk in group with atherosclerosis features was higher than in group of pts without atherosclerosis (p=0,0001).A positive correlation between total risk of coronary complications and CRP concentration (r=0,27, p=0,02). Conclusion. Classical and some "ersatz" risk factors are of considerable significance in atherosclerosis and connected with it CVD progression. Multiple-factor analysis of different indices and evaluation of their role in the CVD development in SLE pts are essential for examination of mechanisms of early atherosclerosis development.
References
1. <div><p>Petri М., Perez-Gulthann S., Spence D. el al. Risk factors Cor coronary artery disease in patients with systemic erythematosus. Am. J Med., 1992, 93, 513-519</p><p>Manzi S., Meilahn E,N., Rairie J. E. et al. Age-specific incidens rales of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framingham Study. Am. J. Epidemiol., 1997, 145, 408-415</p><p>Hahn B.H. Systemic lupus erythematosus and acceleraied atherosclerosis. New Engl. J. Med., 2003, 349, 2379-2380</p><p>Насонои Е.Л. Проблема атеротромбозя в ревматологии. Вест. РАМН. 2003. 7, 6-10</p><p>Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кард иол,, 1999, 2. 81-85</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер. архив, 2002, 5, 80-85</p><p>Ridker Р. М. Clinical application of C-reaciive protein for cardiovascular disease detection and prevention. Circulation, 2003, 107, 363-369</p><p>Esdule J.M., Abrahamowicz М., Grodzicky T. et al. Traditional Framingham Risk factor fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheum., 2001, 44, 2331-2337</p><p>Насонов Е.Л. Антифосфолипндный синдром. М., Изд- по "Литтерра”, 2004</p><p>Перова Н.В. Косматова О.В. Простой метод оценки снижения суммарного коронарного риска при лечении гипертонии и гиперлипидемии. Атмосфера. Кардиология, 2002, 3, 23-25</p><p>Urowitz М., Glad man D., Bruce I. Atherosclerosis and systemic lupus erythematosus. Curr. Opin. Rheumat., 2000, 2, 19-23</p><p>Bruce I.N., Urowiiz M.B., Gladman D.D. et al. Risk factors for coronary heart disease in women with systemic lupus erythemutosus. Arthr. Rheum., 2003, 48, 3159-3167</p><p>Esdale J.M., Abrahamowicz М., Grodzicky T. et al. Traditional Framingham Risk factor fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheum., 2001, 44, 2331-2337</p><p>Алекберова 3.C., Попкова T.B., Насонов Е.Л. и др. Липидно-белковые показатели системы транспорта холестерина крови при системной красной волчанке. Тер, архив., 1999, 5, 34-38</p><p>Van Doornum S., McColl G., Wicks l.P. Accelerated atherosclerosis. An exlraarticular feature of rheumatoid arthritis? Arthr. Rheum., 2002, 46, 862-S73</p><p>Svenungsson E., Jensen-Urstad K„ Heimburger M. el al. Risk factors for cardiovascular disease in systemic lupus ery- Ihemalosus. Circulation, 2001, 104, 1887-1893</p><p>Ilowite NT. Hyperlipidemia and the rheumatic diseases. Curr. Opin. Rheumatol., 1996, 8, 455-458</p><p>Formiga F., Meco J.F., Pinto X. et al. Lipid and lipoprotein levels in premenopausal patients. Lupus, 2001, 10, 359363</p><p>Bruce J.N., Gladman D.D., Urowiiz M.B. Premature atherosclerosis in systemic lupus erythematosus. Rheum. Dis. Clin. North Amer., 2000, 26, 257-278</p><p>Borba E.F., Bonfa E., Vinagre CGC. Et al. Chylomicron metabolism in markedly altered in systemic lupus erythematosus. Arthr. Rheum., 2000, 43, 1033-1040</p><p>Rosenson R.S. Myocardial injure: the acute phase response and lipoprotein metabolism. J, Am. Coll. Cardiol., 1993, 22, 933-940</p><p>Lahitn R.G., Rivkin E., Cavanagh I., Romano P. Low levels of total cholesterol, high density lipoprotein and apolipoprotein AI in association with anticardiolipin anti bodiers in patients with systemic lupus erythematosus. Arlhr. Rheum., 1993, 36, 1566-1674</p><p>George J., Harals D., Gilburd B. et al. Aiherosclerosis- relaied markers in systemic lupus erythematosus patients: the role оГ humoral immunity in enhanced atherogenesis. Lupus, 1999, 8, 220-226</p><p>Wierzbicki A.S. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus, 2000, 9, 194-201</p><p>Petri M. Cardiovascular morbidity in the Hopkins Lupus Cohort. In. Atherosclerosis and autoimmunity. Ed. Y Schoenfeld., D Harals., G Wick. Elsevier, 2001, 249-254</p><p>Manzi S., Selzer F., Sutton-Tyrrell K. et al. Prevalence and risk factors of carotid plague in women with systemic lupus eryihcmatosus. Arthr. Rheum., 1999, 42, 51-60</p><p>Falaschi F., Raveli A., Martignoni A. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis ill juvenily-onset systemic lupus erythematosus. Arthr. Rheum., 2000, 43, 6, 1405-1409</p><p>Whelton P.K., He J. Elevated systolic blood pressure and risk of cardiovascular and renal disease; overview of evidence from observational epidemiological studies and randomized eonlrolled trials. Am. Heart J., 1999, 138, 211-219</p><p>Collins R., Pelo R., MacMahon S.W. Blood pressure, stroke and coronary heart disease. II: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet, 1990, 335, 827-838</p><p>Garnero A., Fasciolo D., Accnrrdo S. Cardiac risk factors in paiienls with rheumatoid arthritis (abstract|. Ann. Rheum. Dis., 1999, suppl, 69-70</p><p>Talura M-С., Heinrich J., Junker R. et al. C-reactive protein and the severity of alherosclerosis in myocardial infarction patients with stable angina pectoris. Eur. Heart J., 2000, 21, 1000-1008</p><p>Gatcia-Moll X. Zouridakis E., Cole D., Kaski J.G. C- reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur. Heart J., 2000, 21, 1598-1606</p><p>Margaglione М., Cappucci G., Colaizzo D, et al. C-reactive protein in offspring is associated with occurrence of myocardial infarction in firsl-degree relatives. Arierioscler. Thromb. Vase. Biol,, 2000, 20, 198-203</p><p>Haverknte F., Thompson S.G., Pyke S.D.M. et al, Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet, 1997, 349. 462-466</p><p>Rohde L.E., Hennekens C.H., Ridker P.M. Survey of C- reactive protein and cardiovascular risk factors in apparently healthy men. Am. J. Cardiol., 1999, 84, 1018-1022</p><p>Rohde L.E., Hennekens C.H., Ridker P.M. Survey of C- reactive protein and cardiovascular risk factors in apparently healthy men. Am. J. Cardiol., 1999, 84, 1018-1022</p><p>Albert M.A., Glynn R.J., Paul M Ridker P.M. Plasma concentration of C-Reaclive Protein and the calculated Framingham coronary heart disease risk score. Circulation, 2003, 108, 161-165</p><p>Ridker P., Hennekens C., Buring J.E., Rifai N, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med,, 2000, 342, 836-843</p><p>Ridker P.M., Glynn R.J, Hennekens C.H. C-reacive protein adds tp the predictive value of total and HDH cholesterol in determining risk of first myocardial infarction. Circulation, 1998, 99, 2007-2011</p></div><br />
Review
For citations:
Popkova T.V., Alekberova Z.S., Aleksandrova E.N., Bulgakova O.V., Nassonov E.L. Cardiovascular disturbances and atherosclerosis risk Гасtore in systemic lupus erythematosus. Rheumatology Science and Practice. 2004;42(4):10-14. (In Russ.) https://doi.org/10.14412/1995-4484-2004-795
Views:
919
Email this article 